Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262193 · ClinicalTrials.gov registry record · Phase 2
Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
A Phase 2 study, sponsored by Wayne State University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT04262193 is a Phase 2 study that was terminated before completion, run by Wayne State University. The registered enrollment target is 37 participants.
The verdict
NCT04262193, a Phase 2 study, was terminated before completion, sponsored by Wayne State University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to investigate whether suvorexant improves outpatient opioid abstinence and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence outcome. 120 participants with opioid use disorder (OUD) will complete this intent-to-treat study.
Interventions
- DRUG Suvorexant
- DRUG Suvorexant Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04262193
The ClinicalTrials.gov registry entry for NCT04262193 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Suvorexant is the first listed.
NCT04262193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04262193 about?
NCT04262193 is a clinical study titled "Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder". Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency and opioid abstinence, and whether these outcomes are independent of one another. This will be the first study to invest...
What is the current status of trial NCT04262193?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2021-02-01. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT04262193?
The interventions under investigation include: Suvorexant (DRUG), Suvorexant Placebo (DRUG).
Who is sponsoring clinical trial NCT04262193?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.